Canada Markets open in 7 hrs 19 mins

Vaxil Bio Ltd. (VXL.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.10500.0000 (0.00%)
At close: 3:59PM EDT
Full screen
Previous Close0.1050
Open0.1100
Bid0.1050 x 0
Ask0.1100 x 0
Day's Range0.1000 - 0.1100
52 Week Range0.0250 - 0.3350
Volume271,185
Avg. Volume722,955
Market Cap10.969M
Beta (5Y Monthly)-3.94
PE Ratio (TTM)N/A
EPS (TTM)-0.0130
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Vaxil Provides Update of Conversion of Previously Issued Convertible Debt and the Granting of Options

    Not for distribution by US newswire or in United States NESS-ZIONA, Israel, Sept. 17, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announced that effective September 17, 2020 (the “Effective Date”), the Company converted all of its outstanding convertible debentures, in the principle amount of $36,000, into 740,086 common shares of the Company (“Common Shares”).  Interest amounting to $2,209 was converted into 20,086 Common Shares at the market price of the Common Shares, being CAD$0.10The Company also wishes to announce the granting, of 200,000 stock options (the “Consultant Options”) to two consultants, issued pursuant to the Company's stock option plan (the "SOP"), exercisable into an equal amount of Common Shares at an exercise price of CAD $0.12 per Share (the "Consultant Options"). 100,000 of the Consultant Options shall vest in three equal installments with 1/3 vesting on the Effective Date (the “Initial Grant”), 1/3 on the 6 month anniversary of the Initial Grant and the last 1/3 on the 12 month anniversary of the Initial Grant. The remaining 100,000 options shall vest in three equal installments with 1/3 vesting on the one-year anniversary of the Initial Grant, 1/3 on the 2 year anniversary of the Initial Grant and the last 1/3 on the 3 year anniversary of the Initial Grant. All Consultant Options shall expire on the 5th anniversary of the Initial Grant.Finally, the Company wishes to announce that following the successful in vivo study (previously announced on September 8, 2020), the Company granted 1.4 million stock options in aggregate to the CEO and CFO, pursuant to the terms of the SOP, exercisable into an equal amount of  Common Shares at an exercise price of CAD $0.12 per Common Share (the "Management Options"). One third of the Management Options vest immediately (the "Initial Date"), one-third vest on the one-year anniversary of the Initial Date, and the remaining amount on the second anniversary of the Initial Date. The Management Options expire 5 years from the Initial Date.ABOUT VAXIL Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The company aims to continue to develop ImMucin™, a COVID-19 and a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit™, Vaxil’s proprietary bioinformatic approach. These signal pepdies induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.The Company is not making any express or implied claims that it has completed developing or will be successful in developing a COVID-19 (or SARS-CoV-2) vaccine at this time.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Disclaimer: The Company cautions that COVID-19 Vaccine Development is still under early stage research and development and is not making any express or implied claims that it has the ability to eliminate the COVID-19 virus at this time. The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.CONTACT INFORMATION For further information please visit http://vaxil-bio.com/ or contact: David Goren, CEO -- info@vaxil-bio.com, +972 (52) 720-6000

  • GlobeNewswire

    Vaxil Announces Positive Results on CorVax™ in vivo Study

    NOT FOR DISTRIBUTION BY US NEWSWIRE OR IN UNITED STATESNESS-ZIONA, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that it has achieved positive results for the in vivo (animal) immunogenicity study which commenced on July 14, 2020. The experiments, performed at the Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Sourasky Medical Center in Israel (the “Tel Aviv Sourasky Medical Centre”) were designed to evaluate, in vivo, the immune response to CorVax™. The results successfully demonstrated both cellular and humoral responses to multiple signal peptides as well as to CorVax™, composed of multiple signal peptides. These results further confirm the potential in the design of Vaxil’s COVID-19 vaccine candidate and provide additional evidence that it generates the anticipated immune response. A total of three injections were inoculated in two mouse strains to better simulate the human immune environment for which CorVax™ was specifically designed. Both mouse strains exhibited a humoral response, developing antibodies as early as 10 days after last injection. Both strains also displayed activated T cells against the signal peptides.“We are delighted with these results, which indicate that further work is warranted to solidify the evidence behind the success of this study,” said Dr. David Hagin, Director of the Allergy and Clinical Immunology Unit at the Tel Aviv Medical Sourasky Center, and continued “from the outset, I was intrigued by Vaxil’s novel solution to a potential COVID-19 vaccine. We are seeing hundreds of patients at our hospital, daily, and therefore, to be involved in developing a potential solution to a global pandemic is particularly fulfilling.”“We are very pleased with the outcome of this study, and will now weigh next steps to continue to produce more data, eventually to achieve approval to launch a clinical trial,” said David Goren, Vaxil’s Chairman and Chief Executive Officer, and continued, “our collaboration with Dr. Hagin and his team at the Tel Aviv Sourasky Medical Centre is extremely effective and I thank Dr. Hagin and his team for their outstanding commitment and professionalism.” The study was performed by a third-party world leading tertiary medical center according to Israeli regulations and the results are expected to be published in the future.We expect to provide a further update within the next eight weeks.ABOUT VAXIL Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The company aims to continue to develop ImMucin™, a COVID-19 and a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit™, Vaxil’s proprietary bioinformatic approach. These signal pepdies induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells. The Company is not making any express or implied claims that it has completed developing or will be successful in developing a COVID-19 (or SARS-CoV-2) vaccine at this time.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Disclaimer: The Company cautions that COVID-19 Vaccine Development is still under early stage research and development and is not making any express or implied claims that it has the ability to eliminate the COVID-19 virus at this time. The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.CONTACT INFORMATION For further information please visit http://vaxil-bio.com/ or contact: David Goren, CEO -- info@vaxil-bio.com, +972 (52) 720-6000

  • GlobeNewswire

    Vaxil Provides Update on In Vivo Study

    Not for distribution by US newswire or in United StatesNESS-ZIONA, Israel, Aug. 27, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, would like to provide an update on the following: On July 20, 2020, the Company announced the commencement of the in vivo (animal) study for Vaxil’s COVID-19 vaccine candidate (Corvax™), under the guidance of Dr. Hagin, Director of the Allergy and Clinical Immunology Unit at the Tel Aviv Medical Center. The experiment was designed to evaluate the immune response to Vaxil’s Corvax™ and was commenced with the first animal injection administered on July 14, 2020.Over the last few weeks, Corvax™ injections were administered and are now complete. The Company is now proceeding to evaluate the results and expects to complete this process including analyses during the next four to six weeks, at which time it will announce results and next steps.“We are acutely aware that the market in general, and our shareholders specifically, are anticipating our progress, and would like more frequent updates, however, the nature of the science is such that experiments take time and cannot be accelerated,” said David Goren, Vaxil’s Chairman and Chief Executive Officer, and continued, “we will continue to apply best practice in our science and update shareholders when we have credible and meaningful information to report.”ABOUT VAXIL Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The company aims to continue to develop ImMucin™, a COVID-19 and a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit™, Vaxil’s proprietary bioinformatic approach. These signal pepdies induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.The Company is not making any express or implied claims that it has completed developing or will be successful in developing a COVID-19 (or SARS-CoV-2) vaccine at this time.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Disclaimer: The Company cautions that COVID-19 Vaccine Development is still under early stage research and development and is not making any express or implied claims that it has the ability to eliminate the COVID-19 virus at this time. The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.CONTACT INFORMATION For further information please visit http://vaxil-bio.com/ or contact: David Goren, CEO -- info@vaxil-bio.com, +972 (52) 720-6000